GlassScriptPhysician profile
Khalil Michael Saliba
NPI 1679544340
$27,259.00
in general payments reported to CMS, 2019-2025
31 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,237 · 2020: $985 · 2021: $12K · 2022: $10K · 2023: $963 · 2024: $649 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,896.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $19,879.35 | 2021-2024 | Qelbree |
| Janssen Pharmaceuticals, INC | $1,908.32 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $1,061.05 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $732.60 | 2019-2025 | Uzedy |
| Abbvie INC. | $660.12 | 2021-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $594.64 | 2019-2024 | Abilify Maintena, Rexulti |
| Axsome Therapeutics, INC. | $409.66 | 2023-2025 | Auvelity |
| Corium, LLC | $376.00 | 2021-2025 | Azstarys |
| Allergan, INC. | $275.41 | 2019 | |
| Alkermes, INC. | $161.20 | 2019-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $152.26 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $142.70 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $141.17 | 2022-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $127.55 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $76.80 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $66.70 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.52 | 2021-2022 | |
| Lundbeck LLC | $52.11 | 2019-2022 | |
| Eisai INC. | $41.36 | 2021 | |
| Genentech USA, INC. | $40.49 | 2019 | |
| Neos Therapeutics, LP | $38.36 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $37.93 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $36.83 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $35.57 | 2025 | Jornay Pm |
| Tris Pharma INC | $35.13 | 2020-2022 | |
| Adlon Therapeutics L.P. | $26.36 | 2019-2021 | |
| Neuronetics, INC. | $24.85 | 2019 | |
| Shire North American Group INC | $21.60 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.93 | 2019 | |
| Kaleo, INC. | $12.79 | 2020 | |
| Almatica Pharma LLC | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalil Saliba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.